Bob Nelsen's guest appearances

Bob Nelsen

The Long Run with Luke Timmerman

The Readout Loud

Axios Re:Cap

Scott Gottlieb

John Maraganore

Meg Tirrell

Chris Garabedian

Alexis Borisy

Elon Musk

George Yancopoulos

Michael Gilman

George Scangos

Ethan Weiss

Andrew Yang

Pete Buttigieg

Amy Klobuchar

Howard Schultz

Jeff Bezos

OwlTail

Bob Nelsen of ARCH Venture Partners on long-term trends in biotech investing.

Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing

On this year's first episode, STAT Washington correspondent Lev Facher joins us to break down the implications of a Democrat-controlled Senate. Then, our colleague Erin Brodwin calls in to talk about CES, the massive tech conference taking place next week. Finally, we chat with Bob Nelsen, a biotech venture capitalist and one of the few people who saw the coming pandemic with clarity months before everyone else, about what's ahead in 2021.

Episode 142: Bob Nelsen on the pandemic's next phase, plus Biden's biopharma plans & a CES preview

AstraZeneca and the University of Oxford today reported promising efficacy data for their COVID-19 vaccine, which has less stringent storage requirements than the Pfizer and Moderna vaccines and which may be distributed earlier in developing countries. Dan digs into the state of vaccine and therapeutics manufacturing with Bob Nelsen, a successful biotech investor who today launched Resilience, a giant new pharma production platform that he believes will prepare America for its next major health challenges.Plus, Axios health care editor Sam Baker joins to discuss AstraZeneca’s interim analysis. Learn more about your ad choices. Visit megaphone.fm/adchoices

AstraZeneca and the University of Oxford today reported promising efficacy data for their COVID-19 vaccine, which has less stringent storage requirements than the Pfizer and Moderna vaccines and which may be distributed earlier in developing countries. Dan digs into the state of vaccine and therapeutics manufacturing with Bob Nelsen, a successful biotech investor who today launched Resilience, a giant new pharma production platform that he believes will prepare America for its next major health challenges.Plus, Axios health care editor Sam Baker joins to discuss AstraZeneca’s interim analysis. Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Biotech investor Bob Nelsen on AstraZeneca and his plan to revolutionize pharma